🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are attending the CAR-TCR conference! The virtual event is being held Aug 30 - Sep 2; join us to learn more about our CAR development capabilities. bit.ly/3B8nXLE #antibodies #conference $IPA

Check out the presentation given by Dr. Debby Kruijsen at this year’s Biologics UK, "Funneling while maintaining diversity: Key strategies of therapeutic antibody campaigns." youtu.be/ijXnNsIesCg $IPA #biologicsUK #antibodydiscovery

We are pleased to be participating in the Emerging Therapeutics Ovarian Cancer Symposium hosted by the Antibody Society. The event is being held today to discuss and raise awareness about the use of antibody therapeutics for ovarian cancer. bit.ly/3yeXo5A $IPA

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre. Follow the link below for more information: bit.ly/3ad9Ysx $IPA #Collaboration Laboratoires Pierre Fabre

ImmunoPrecise to present at The Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021. Visit our website to learn more: bit.ly/3r71Rr6 $IPA #antibody #discovery #investor #conference

ImmunoPrecise (IPA) Updates: SARS-CoV-2 PolyTope™, Multi-Antibody Cocktail and Omicron Variant Analysis. Follow the link below to read the full press release: bit.ly/3G1FyY8 $IPA #SARSCoV2 #PolyTope

Bring your toughest antibody target challenge to the Antibody Engineering & Therapeutics conference December 12-16 in San Diego and CHALLENGE US. Join ImmunoPrecise (IPA) and Eurofins Discovery at booth #307 and virtually. bit.ly/3rNYTrC $IPA #ChallengeUs

$IPA is hiring a Client Relations Manager Europe immunoprecise.com/wp-content/upl…

We are excited to announce the relocation of our European subsidiary to a LEED-certified campus to advance our antibody research operations and environmental sustainability. Visit our website to read the full press release: bit.ly/3GKI8Cr $IPA

Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission | Business Wire businesswire.com/news/home/2022…

IPA super-powers capabilities with Biostrand's new method for computational encoding of omics and powering drug discovery with advanced AI. Full press release: bit.ly/3uCsCUj #AI $IPA #biotechnology #Omics #drugdiscovery #bioinformatics

A HUB of biotherapeutic intelligence with a hybrid of expertise and visionary technologies, bringing Ab discovery CRO services, and precision medicine into view and making patient omic data analysis infinitely more meaningful, accessible, and faster. #IPA bit.ly/3KGofyo

Introducing a new LENSai on natural, artificial, and complex biological data that brings precision medicine into view. Gain access to multi-omic data and analytics to discover life-saving, precision drugs faster. bit.ly/3xywXv3 #precisionmedicine $IPA #antibodies

IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern | BioSpace biospace.com/article/releas…

IPA is looking forward to embarking on the exciting opportunities and new partnerships that took shape last week at BIO International. We are more excited than ever to introduce a whole new approach to making personalized medicine a reality! bit.ly/3Nde5Wp #BIO2022 $IPA

Our vivarium size has doubled! New space allows for implementation of new in vivo service offerings, increasing our already comprehensive full-service #antibody discovery cycle. Learn more: bit.ly/3BuMYUk $IPA #immunoprecise #antibodydiscovery #drugdiscovery #biotech

Join us at FOB to learn about IPA's proven platforms for maximizing functional diversity, and a detailed analysis of high-throughput characterization to detect clinically relevant candidates. Download the poster here: bit.ly/3DQh3P9 $IPA #FOB

See Dr. Kruijsen's presentation on "Selection of clinically relevant VHH antibodies via cell-based phage display selection and characterizations". Contact [email protected] or go to bit.ly/3TR1bk9 $IPA #hubX

Custom designed VHH programs from IPA are tailored to very specific needs. Let's discuss yours — and the advantages of our display technologies and single domain antibody discovery. See you at AET! bit.ly/3bInXe2 $IPA #aet

IPA leads the industry in full-service antibody discovery - from target analysis to optimized lead candidates. Visit us to learn more or complete this form to start a conversation about your program. bit.ly/3iG23LE $IPA #aet